Literature DB >> 26989268

Computational and experimental structure-reactivity relationships: evidence for a side reaction in Alpine-Borane reductions of d-benzaldehydes.

Hui Zhu1, N Soledad Reyes1, Matthew P Meyer1.   

Abstract

Extraordinary stereoselectivity, approaching 100%, has been reported in the reductions of d-benzaldehydes by B-isopinocampheyl-9-borabicyclo[3.3.1]nonane (Alpine-Borane). This is likely because of the extreme size disparity of groups on either side of the carbonyl. Here, we present a structure-reactivity study whereby the reductions of variably substituted d-benzaldehydes are explored using highly sensitive measures for enantiomeric excess and relative reactivity. These results are compared to the relative rates predicted from density functional calculations. The results indicate that 2,6-disubstitution adversely affects the stereoselectivity by means of a non-selective reduction via the dehydroboration product of Alpine-Borane, 9-borabicyclo[3.3.1]nonane.

Entities:  

Year:  2009        PMID: 26989268      PMCID: PMC4792110          DOI: 10.1016/j.tetlet.2009.09.109

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  3 in total

Review 1.  Chemical basis for enzyme catalysis.

Authors:  T C Bruice; S J Benkovic
Journal:  Biochemistry       Date:  2000-05-30       Impact factor: 3.162

2.  Isotope effects and the nature of enantioselectivity in the shi epoxidation. The importance of asynchronicity.

Authors:  Daniel A Singleton; Zhihong Wang
Journal:  J Am Chem Soc       Date:  2005-05-11       Impact factor: 15.419

3.  How borane reagents based on alpha-pinene control stereoselectivity in the reductions of carbonyl groups with different stereogenic elements. 3. The effect of the relative size and conformation of the carbonyl substituents on the stereoselectivity of the Ipc(2)BCl, Eap(2)BCl, B-t-Bu-IpcBCl, and B-t-Bu-EapBCl reagents. A semiempirical study

Authors: 
Journal:  J Org Chem       Date:  2000-10-20       Impact factor: 4.354

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.